ORYZON Expands Patent Protection for Iadademstat with Grant Decision in Mexico Covering Combinations with PD-1/PD-L1 Inhibitors

Core Insights - Oryzon Genomics has received patent protection for its cancer therapy involving iadademstat in combination with PD-1 or PD-L1 inhibitors, specifically targeting small cell lung cancer (SCLC) [1][2] - The patent is expected to provide protection until at least 2040, enhancing Oryzon's intellectual property portfolio globally [2][3] - Iadademstat is currently undergoing clinical trials in combination with immune checkpoint inhibitors for extensive-stage SCLC, with promising preliminary results [3][5] Company Overview - Oryzon Genomics, founded in 2000 and headquartered in Barcelona, Spain, is a clinical-stage biopharmaceutical company focused on epigenetics and personalized medicine for oncology and CNS disorders [4] - The company has a robust clinical portfolio, including two LSD1 inhibitors: iadademstat for oncology and vafidemstat for CNS disorders, with ongoing Phase I and II studies [4][5] - Iadademstat has shown a 100% overall response rate in acute myeloid leukemia (AML) and is being evaluated in various hematological and solid tumors, including SCLC [5][6] Clinical Development - Iadademstat is being tested in two ongoing clinical trials for extensive-stage SCLC, one sponsored by the U.S. National Cancer Institute and the other by Yale University [3][6] - The drug has demonstrated safety and efficacy in combination with other therapies, including azacitidine and venetoclax for AML, and is also being explored for non-oncological indications [5][6] - Oryzon has received orphan drug designation for SCLC and AML in both the US and EU, indicating its potential significance in treating these conditions [6]